Proactiveinvestors USA & Canada CannPal Animal Therapeutics Ltd https://ca.proactiveinvestors.com Proactiveinvestors USA & Canada CannPal Animal Therapeutics Ltd RSS feed en Thu, 23 May 2019 17:39:27 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - CannPal Animal Therapeutics major shareholder increases stake ]]> https://ca.proactiveinvestors.com/companies/news/220542/cannpal-animal-therapeutics-major-shareholder-increases-stake-220542.html CannPal Animal Therapeutics Ltd (ASX:CP1) has had one of its major shareholders, Merchant Funds Management, increase its stake to 19.61% from 18.61%.

The increase was the result of a series of on-market trades, the most recent being the purchase of 1 million shares last Thursday 16 May for $145,478.

Merchant is a boutique Perth-based fund manager focused on early-stage ASX opportunities.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The buying activity from Merchant follows purchases from a number of CannPal board members.

The most recent purchase was from founder and managing director Layton Mills who purchased 65,000 shares via on-market trades earlier this month.

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

]]>
Mon, 20 May 2019 08:32:00 -0400 https://ca.proactiveinvestors.com/companies/news/220542/cannpal-animal-therapeutics-major-shareholder-increases-stake-220542.html
<![CDATA[News - CannPal Animal Therapeutics managing director buys more shares on-market ]]> https://ca.proactiveinvestors.com/companies/news/220079/cannpal-animal-therapeutics-managing-director-buys-more-shares-on-market-220079.html CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills has purchased 65,000 shares in the company via on-market trades.

The $10,075 parcel of shares increases Mills’ total holding in the company to over 7.57 million shares.

READ: CannPal Animal Therapeutics files new patent application as industry-leading research is recognised

The share purchase from Mills follows purchases from Max Johnston in March, chairman Geoff Starr in February, and Robert Clifford in January this year.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals such as dogs and cats.

CPAT-01 is the company’s lead drug candidate under development targeting pain and inflammation control in dogs.

]]>
Mon, 13 May 2019 08:33:00 -0400 https://ca.proactiveinvestors.com/companies/news/220079/cannpal-animal-therapeutics-managing-director-buys-more-shares-on-market-220079.html
<![CDATA[News - CannPal Animal Therapeutics R&D research to be published in leading veterinary journal ]]> https://ca.proactiveinvestors.com/companies/news/218804/cannpal-animal-therapeutics-rd-research-to-be-published-in-leading-veterinary-journal-218804.html CannPal Animal Therapeutics Ltd (ASX:CP1) is being recognised for its robust and leading research into medicinal cannabis treatments for animals through participation in Australia’s largest veterinary conference and publication of its first research abstract.

This will provide the company the opportunity to directly present to 1,400 veterinarians at the Australian Veterinary Association (AVA) Innovation, Research and Development Symposium in May.

CannPal will also reach more than 5,000 through publication of its abstract in the Australian Veterinary Journal (AVJ), which is Australia’s premier veterinary scientific journal.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

Founder and managing director Layton Mills said the presentation and AVJ publication was a significant milestone for the company.

He said: “There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.

“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines”.

“Building a trusting relationship” with vets

“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”

During the AVA Innovation Symposium in Perth next month CannPal’s head of R&D Dr Margaret Curtis will present on the company’s Phase 1 trial results.

This will include the pharmacokinetic, safety, gene expression and inflammatory biomarker results from the robust randomised three group parallel pharmacokinetic study completed in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The AVA event between May 5 and 10 is the largest veterinary conference in Australia, with an average of 1,400 veterinary professionals expected to attend.

It is a platform for industry and animal researchers to present their clinical research and findings directly to the veterinary profession.

The Innovation Symposium will be on Sunday, May 5, and Dr Curtis will present at 3.35pm alongside speakers from world-leading animal health companies such as Bayer, Ceva and Virbac.

Abstracts from the symposium will be published in the AVJ, which is Australia’s premier veterinary scientific journal, reaching an audience of over 5,000 AVA members.

CannPal generates “exciting results”

Dr Curtis said: “This is a great opportunity to get our initial results out into the veterinary fraternity in Australia.

“The AVJ is widely read, and publication of this work will further disseminate the exciting results that CannPal is generating, bringing us closer to potentially approvable cannabis-derived medicines for pets.”

MD Mills said: “Since founding the company, CannPal has placed diligent focus on building a credible and experienced R&D team to complete robust and world leading research on the safety and efficacy of cannabis-derived compounds for companion animals.

“The AVA Symposium is an opportunity for CannPal to start sharing some of that research with the scientific and veterinary community, in the hopes of establishing CannPal as a clear leader in this field.”

READ: CannPal Animal Therapeutics director buys 100,000 shares on-market

CannPal is researching and developing medicines derived from cannabinoids with the aim of providing veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

]]>
Thu, 18 Apr 2019 10:31:00 -0400 https://ca.proactiveinvestors.com/companies/news/218804/cannpal-animal-therapeutics-rd-research-to-be-published-in-leading-veterinary-journal-218804.html
<![CDATA[News - CannPal Animal Therapeutics director buys 100,000 shares on-market ]]> https://ca.proactiveinvestors.com/companies/news/216127/cannpal-animal-therapeutics-director-buys-100000-shares-on-market-216127.html CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive director Robert Johnston has purchased 100,000 shares through on-market trades.

The purchase amounted to $11,911.86 and increased Johnston’s total holding in the company to 300,000 shares.

READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

Last month, CannPal received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

]]>
Mon, 11 Mar 2019 08:19:00 -0400 https://ca.proactiveinvestors.com/companies/news/216127/cannpal-animal-therapeutics-director-buys-100000-shares-on-market-216127.html
<![CDATA[News - CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market ]]> https://ca.proactiveinvestors.com/companies/news/215668/cannpal-animal-therapeutics-sees-lucrative-opportunity-in-cannabinoids-based-animal-health-market-215668.html CannPal Animal Therapeutics Ltd (ASX:CP1) is well placed to benefit from the rapidly growing cannabinoids-based animal health market.

Focusing on animal well-being, particularly companion pets (e.g., cats and dogs) could be lucrative for the company.

According to the American Pet Product Association, annual pet industry expenditure in the U.S. has grown in each of the past 18 years, with Americans estimated to have spent $18.3 billion on veterinary care and $15.5 billion on supplies and over-the-counter medicines in 2018.

READ: CannPal Animal Therapeutics receives approvals for two clinical studies

The company recently received two key ethics approvals to progress the research and development of its lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal hopes to complete recruitment for both studies by mid CY2019.

Elixinol Global gaining traction in the pet space

Many players in the industrial hemp and cannabidiol (CBD) based dietary supplement market are seeing a growing market for their products catering to the pet industry.

This includes Elixinol Global Ltd (ASX:EXL), manufacturer of Edibites, a CBD pet treat specifically formulated for dogs.

Elixinol recently witnessed an increase in private label production which now accounts for around 40% of its U.S. revenue of $32.5 million in 2018, with one large customer in the pet space driving most of the private label growth.

Cannabinoids-based animal health is a niche space that is growing fast and CannPal already has an advantage through its research and product development programs which are well underway.

]]>
Mon, 04 Mar 2019 13:57:00 -0500 https://ca.proactiveinvestors.com/companies/news/215668/cannpal-animal-therapeutics-sees-lucrative-opportunity-in-cannabinoids-based-animal-health-market-215668.html
<![CDATA[News - CannPal Animal Therapeutics receives approvals for two clinical studies ]]> https://ca.proactiveinvestors.com/companies/news/214500/cannpal-animal-therapeutics-receives-approvals-for-two-clinical-studies-214500.html CannPal Animal Therapeutics Ltd (ASX:CP1) has received two key ethics approvals to progress the research and development of lead therapeutic products, CPAT-01 and DermaCann.

CPAT-01 is a pain and inflammatory control being developed for dogs and DermaCann is a nutraceutical product in development to promote canine skin health.

CannPal’s phase IIa clinical study for CPAT-01 will see 60 dogs with osteoarthritis recruited from veterinary clinics across New South Wales and Queensland.

The clinical trial for DermaCann is an eight week efficacy study to explore effects and confirm safety and will see 45 dogs recruited.

CannPal hopes to complete recruitment for both studies by mid CY2019.

READ: CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase

CannPal's founder and managing director Layton Mills said: “I’m delighted that we’re moving into the second Phase for CPAT-01, within just a few months of completing our phase I research activities.

“I’m also pleased that our research and development team has been able to progress the DermaCann project plan with the same momentum via the initiation of our safety and efficacy study, which is a major milestone for our nutraceutical strategy.

“I’m looking forward to commencing our phase II pilot studies for CPAT-01 and the potential to explore commercialisation opportunities for our nutraceutical products in 2019.”

READ: CannPal Animal Therapeutics chairman buys company shares

Yesterday, CannPal’s non-executive chairman Geoff Starr purchased 80,000 shares in the company worth $10,193 via on-market trades.

]]>
Wed, 13 Feb 2019 12:19:00 -0500 https://ca.proactiveinvestors.com/companies/news/214500/cannpal-animal-therapeutics-receives-approvals-for-two-clinical-studies-214500.html
<![CDATA[News - CannPal Animal Therapeutics chairman buys company shares ]]> https://ca.proactiveinvestors.com/companies/news/214490/cannpal-animal-therapeutics-chairman-buys-company-shares-214490.html CannPal Animal Therapeutics Ltd (ASX:CP1) non-executive chairman Geoff Starr has purchased 80,000 shares in the company via on-market trades.

The $10,193 parcel is Starr’s first purchase of company shares and his first step to aligning himself with shareholders.

READ: CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase

CannPal intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The company's lead drug candidate is a cannabis-derived canine pain and inflammation medication.

In the recent December quarterly report chairman Geoff Starr said: “I’m extremely happy with the progress that CannPal has made in the December quarter, and particularly the company’s progress with our nutraceutical program, while maintaining focus on our lead pharmaceutical.

“Our strategy has been to remain focused and diligent in the development of compliant animal health products and that work is beginning to pay off as we’re getting closer towards getting CannPal in a position to explore commercialisation opportunities in 2019.

“I’m looking forward to the team continuing with the same momentum throughout the new-year.”

]]>
Wed, 13 Feb 2019 08:19:00 -0500 https://ca.proactiveinvestors.com/companies/news/214490/cannpal-animal-therapeutics-chairman-buys-company-shares-214490.html
<![CDATA[News - CannPal Animal Therapeutics well capitalised as it moves towards commercialisation phase ]]> https://ca.proactiveinvestors.com/companies/news/213454/cannpal-animal-therapeutics-well-capitalised-as-it-moves-towards-commercialisation-phase-213454.html CannPal Animal Therapeutics Ltd (ASX:CP1) intends to transition from research & development (R&D) to a commercialisation phase as it prepares the trial design for a phase 2A study of its cannabinoid development therapeutic CPAT-01 in animals.

The well-capitalised, Sydney-based company released its quarterly cashflow report and market update for December quarter 2018 earlier today.

READ: CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs

CannPal highlighted its $4.55 million cash balance at the end of the December quarter, comparing it with the $510,000 quarterly cash burn which had primarily related to its R&D costs.

During the quarter, the diligent budget manager received a $297,299 R&D tax refund from the Australian Government and attributed its increase in legal costs and fees in part to collecting the refund.

CannPal confirmed it was fully-funded up to its phase II pilot studies for CPAT-01 and other milestones it has communicated to market, including the commercialisation of its lead nutraceutical product DermaCann.

READ: CannPal Animal Therapeutics director shows faith in company through on-market purchase

CannPal founder and managing director Layton Mills told the market: “I am very excited about the progress that we’re making across our entire portfolio.

“Our work so far continues to build confidence that CannPal will be able to develop and commercialise compliant and evidence-based products for companion animals in the areas of pain and osteoarthritis, as well as skin and joint health.

“I’m looking forward to commencing our Phase 2 pilot studies for CPAT-01 and the potential to explore commercialisation opportunities for our nutraceutical products in 2019.”

CannPal chairman Geoff Star highlighted the team’s momentum, saying “I’m extremely happy with the progress that CannPal has made in the December quarter, and particularly the company’s progress with our nutraceutical program, while maintaining focus on our lead pharmaceutical.

“Our strategy has been to remain focused and diligent in the development of compliant animal health products and that work is beginning to pay off as we’re getting closer towards getting CannPal in a position to explore commercialisation opportunities in 2019.

“I’m looking forward to the team continuing with the same momentum throughout the new year.”

Phase II pilot studies

This quarter, the protocol for the highlighted first study in its phase II program, a phase 2A pilot clinical study of CPAT-01 in client-owned animals with the arthritic bone condition OA, is being worked on.

CannPal will draw on its results from phase I (A&B) studies completed last year, including its phase 1B study of CPAT-01 in more than 48 dogs completed last month, which evaluated the development drug for pain and inflammation control in dogs.

Gene expression studies have revealed clear cannabinoid impact in important pain and inflammatory pathways, supporting proposed pain and inflammatory control claims for CPAT-01.

A Melbourne-based integrated medical lab has been helping CannPal identify the drug’s effects on key chemokine and cytokines associated with the activated pain and inflammatory genes highlighted in the phase I studies.

A kick-off of the study is now expected in the June half-year 2019.

Neutraceutical products

On the nutraceuticals front, CannPal’s New Zealand-based manufacturing partner Jaychem Industries Ltd is also expected to start a canine study of DermaCann, which is being developed as a CBD (cannabidiol)-derived oral skin supplement for dogs.

Auckland-based Jaychem completed laboratory formulation work in the December quarter and will manufacture a batch of formula in the June half for the study, in a start to the formulation stability program.

NSW biotech CannPal will add the safety data from development work and the upcoming skin study results to a dossier for complementary animal health product approval (CAHP) with Australian Pesticides and Veterinary Medicines Australia (APVMA).

CAHP approval would allow animal owners in Australia to buy DermaCann through Australian veterinarians and would represent a significant milestone for the animal pharmaceuticals company.

READ: CannPal Animal Therapeutics caps off busy September quarter

CannPal also worked with the Australian Government’s independent science agency CSIRO last quarter, backed by a $500,000 CSIRO grant, and this is expected to generate additional commercialisation opportunities for CannPal.

The collaborators claimed success from their first phase of study in evaluating the feasibility of using CSIRO’s food-producing technologies to turn CannPal’s oil-based formulations into a powdered product.

CannPal hopes to identify opportunities to use the delivery mechanism for animal nutraceuticals in its pipeline.

Significant shareholders

The tightly-held company’s top 20 shareholders had 68.18% of the company on September 17, with The Trust Company (Australia) Limited <MOF A/C> leading the pack with a 15.8% stake.

CannPal’s other significant shareholders were Gemelli Nominees Pty Ltd, with 9.32%, Pepaanne Pty Ltd <The Chapman Family A/C> (8.23%), founder Layton Patrick Mills <DJS Family A/C> (7.39%) and Tania Maree Vidovic <Star V Family A/A> (7.39%).

 

]]>
Mon, 28 Jan 2019 19:30:00 -0500 https://ca.proactiveinvestors.com/companies/news/213454/cannpal-animal-therapeutics-well-capitalised-as-it-moves-towards-commercialisation-phase-213454.html
<![CDATA[News - CannPal Animal Therapeutics director shows faith in company through on-market purchase ]]> https://ca.proactiveinvestors.com/companies/news/212197/cannpal-animal-therapeutics-director-shows-faith-in-company-through-on-market-purchase-212197.html CannPal Animal Therapeutics Ltd (ASX:CP1) director Rob Clifford has demonstrated his confidence in the company’s unique strategy of developing cannabis-derived medications for animals by acquiring shares on-market.

Clifford, a non-executive director, this week purchased 50,000 shares for an indirect interest.

Through this interest, he now holds more than 480,000 shares, which at an intra-day high of 14 cents today was valued in excess of $67,200.

READ: CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs

Last month CannPal completed dosing for the phase 1B study of its lead drug candidate CPAT-01, which is being developed as a pain and inflammatory control for dogs.

More than 48 Beagles and Foxhounds were recruited for the study across various weights and ages with no adverse events reported in dogs across all treatment groups.

Gene expression studies so far have revealed clear cannabinoid impact in important pain and inflammatory pathways supporting the proposed pain and inflammatory control claims for CPAT-01.

READ: CannPal Animal Therapeutics director acquires further shares on-market

CannPal is now working with a Melbourne-based integrated medical laboratory to identify the drug’s effects on key chemokine and cytokines associated with the activated pain and inflammatory genes highlighted in the phase I studies.

The results of this in conjunction with the gene expression data will support the dose justification for CPAT-01 before commencing the clinical program.

Phase II study planned

CannPal has generated significant data on the pharmacokinetic and gene expression profiles of cannabinoids in dogs.

This will be used to begin protocol development for the first phase II study, a pilot dose determination study in client-owned animals with OA to clinically validate the effects seen in phase I studies.

The company aims to begin recruitment for this study during the current quarter.

Testing in cats

CannPal has also received ethics approvals to commence the testing of CPAT-01 in cats.

As cats represent over 25% of the companion animal drug market, there’s a clear unmet need for safe therapeutics that can be used long-term to treat pain and inflammation.

]]>
Wed, 09 Jan 2019 14:54:00 -0500 https://ca.proactiveinvestors.com/companies/news/212197/cannpal-animal-therapeutics-director-shows-faith-in-company-through-on-market-purchase-212197.html
<![CDATA[News - CannPal Animal Therapeutics concludes successful phase 1B cannabinoid study in dogs ]]> https://ca.proactiveinvestors.com/companies/news/211004/cannpal-animal-therapeutics-concludes-successful-phase-1b-cannabinoid-study-in-dogs-211004.html CannPal Animal Therapeutics Ltd (ASX:CP1) has successfully completed dosing for the phase 1B study of its lead drug candidate CPAT-01, being developed as a pain and inflammatory control for dogs.

More than 48 Beagles and Foxhounds were recruited for the study across various weights and ages.

Importantly, no adverse events were reported in dogs across all treatment groups.

READ: CannPal Animal Therapeutics caps off busy September quarter

The gene expression studies so far have revealed clear cannabinoid impact in important pain and inflammatory pathways supporting the proposed pain and inflammatory control claims for CPAT-01.

CannPal is now working with a Melbourne-based integrated medical laboratory to identify the drug’s effects on key chemokine and cytokines that are associated with the activated pain and inflammatory genes highlighted in the phase I studies.

The results of this in conjunction with the gene expression data will support the dose justification for CPAT-01 prior to commencing the clinical program.

READ: CannPal Animal Therapeutics director acquires further shares on-market

CannPal founder and managing director Layton Mills said: “I am very pleased at the speed in which we are progressing through the CPAT-01 development plan, but more importantly, the significant amounts of data we are collecting along the way.

“Our vision is to be one of the first animal health companies to provide veterinarians with GMP produced and regulatory approved cannabinoid-derived therapeutics for pets.

“We have been strict on resources and strong on creativity to ensure we remain well capitalised to continue with the development of CPAT-01 in 2019, which wouldn’t be possible without the help and support of our experienced research partners.”

Phase II study protocol development

The company has now generated significant data on the pharmacokinetic and gene expression profiles of cannabinoids in dogs.

This data will be used to commence the protocol development for the first phase II study, a pilot dose determination study in client-owned animals with osteoarthritis to clinically validate the effects seen in phase I studies.

CannPal is aiming to commence recruitment for this study in Q1 2019.

CPAT-01C cat study

The company has also received ethics approvals to commence the testing of CPAT-01 in cats.

Cats represent over 25% of the companion animal drug market and there’s a clear unmet need for safe therapeutics that can be used long-term to treat pain and inflammation in felines.

Over 20 cats have been recruited for the study across varying weights and ages.

The animal phase of the study was originally planned for Q4 2018 but is now expected to commence early in 2019 across multiple research sites.

]]>
Wed, 12 Dec 2018 08:46:00 -0500 https://ca.proactiveinvestors.com/companies/news/211004/cannpal-animal-therapeutics-concludes-successful-phase-1b-cannabinoid-study-in-dogs-211004.html
<![CDATA[News - CannPal Animal Therapeutics director acquires further shares on-market ]]> https://ca.proactiveinvestors.com/companies/news/209622/cannpal-animal-therapeutics-director-acquires-further-shares-on-market-209622.html CannPal Animal Therapeutics Ltd (ASX:CP1) director Max Johnston has shown confidence in the company’s development of cannabis-derived medications for animals by acquiring shares on-market.

Johnson, a non-executive director, has this week acquired more than 35,600 shares with a total value of almost $5,000.

READ: CannPal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications

This takes the total number of shares held in indirect interest to 200,000 shares.

Last month Johnston acquired almost 64,400 shares with a total value of more than $9,000.

READ: CannPal Animal Therapeutics caps off busy September quarter

CannPal had a busy September quarter entering two research agreements and advancing its lead cannabis-derived drug candidate CPAT-01.

CPAT-01D, a pain treatment for dogs, received ethics approvals and the CPAT-01 development program was expanded to include cats - CPAT-01C.

48 beagles and foxhounds enrolled

The phase Ib study for CPAT-01D is underway and the live phase is expected to be completed by the end of this quarter.

This study has enrolled 48 beagles and foxhounds of both sexes in wide weight and age ranges after clinical screening and examination.

At September 30 the company had a cash balance of $4.72 million, which was in line with budget forecasts and sufficient to continue with its research and development activities in subsequent months.

READ: CannPal Animal Therapeutics’ sponsor fee for lead animal drug candidate waived by US FDA

CannPal was founded by a team of experienced executives to establish a new standard of care in animal health by providing veterinarians with regulatory approved, Cannabinoid-based pharmaceuticals.

The company has identified an opportunity to develop first-in-class medicines for cats, dogs and horses, derived from the cannabis plant.

]]>
Wed, 21 Nov 2018 09:41:00 -0500 https://ca.proactiveinvestors.com/companies/news/209622/cannpal-animal-therapeutics-director-acquires-further-shares-on-market-209622.html